- Previous close
118.03 - Open
118.59 - Bid 118.37 x 1000
- Ask 118.40 x 1000
- Day's range
118.14 - 119.07 - 52-week range
92.94 - 148.15 - Volume
2,466,009 - Avg. Volume
4,059,745 - Market cap (intra-day)
522.965B - Beta (5Y monthly) 0.15
- PE ratio (TTM)
40.26 - EPS (TTM)
2.94 - Earnings date 6 Nov 2024
- Forward dividend & yield 1.45 (1.23%)
- Ex-dividend date 16 Aug 2024
- 1y target est
142.24
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
www.novonordisk.com69,260
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Biotechnology
Industry
Recent news: NVO
View more
Related videos: NVO
Performance overview: NVO
Trailing total returns as of 17/10/2024, which may include dividends or other distributions. Benchmark is
.YTD return
1-year return
3-year return
5-year return
Compare to: NVO
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: NVO
View moreValuation measures
Market cap
521.44B
Enterprise value
520.62B
Trailing P/E
40.20
Forward P/E
29.50
PEG ratio (5-yr expected)
1.81
Price/sales (ttm)
14.01
Price/book (mrq)
31.93
Enterprise value/revenue
13.83
Enterprise value/EBITDA
26.65
Financial highlights
Profitability and income statement
Profit margin
34.84%
Return on assets (ttm)
22.80%
Return on equity (ttm)
88.57%
Revenue (ttm)
258B
Net income avi to common (ttm)
89.9B
Diluted EPS (ttm)
2.94
Balance sheet and cash flow
Total cash (mrq)
62.65B
Total debt/equity (mrq)
50.71%
Levered free cash flow (ttm)
54.49B